Current Opinion in Oncology最新文献

Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-27 DOI: 10.1097/CCO.0000000000001119

Michel Meyers, Oumnia Mouna, Mireille Langouo

{"title":"Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?","authors":"Michel Meyers, Oumnia Mouna, Mireille Langouo","doi":"10.1097/CCO.0000000000001119","DOIUrl":"10.1097/CCO.0000000000001119","url":null,"abstract":"Purpose of review: This review evaluates by analyzing recent studies whether pathological complete response (pCR) can be used as a reliable surrogate marker for overall survival (OS) in melanoma treated with neoadjuvant immunotherapy.Recent findings: Trials like Neo-Combi, Neo-Trio and COMBI-Neo show that pCR is crucial for long-term success in targeted therapy for melanoma, while studies like OpACIN-neo and SWOG S1801 demonstrate that immunotherapy can provide durable benefits even with partial responses. Findings from NADINA and the INMC analysis highlight that immunotherapy achieves higher pathologic response rates and improved survival outcomes, offering broader benefits compared to the pCR-dependent outcomes of targeted therapy.Summary: pCR serves as a critical prognostic biomarker across cancer types, with strong validation in breast cancer where it predicts long-term survival, particularly in aggressive subtypes like triple-negative and HER2-positive breast cancer. In melanoma, pCR is gaining prominence as a surrogate marker in neoadjuvant therapies, with its predictive value varying between targeted treatments - where achieving pCR is essential - and immunotherapies, which provide durable survival benefits even with partial responses. Despite its potential, the role of pCR as a universally reliable surrogate endpoint in melanoma requires further validation through cancer-specific studies to ensure accurate treatment guidance and personalized care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"116-120"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can febrile neutropenia re-invent its self?

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001116

Aspasia Georgala, Jean Klastersky

{"title":"Can febrile neutropenia re-invent its self?","authors":"Aspasia Georgala, Jean Klastersky","doi":"10.1097/CCO.0000000000001116","DOIUrl":"10.1097/CCO.0000000000001116","url":null,"abstract":"Purpose of review: Febrile neutropenia as a complication of cytotoxic chemotherapies, remains a major event in the medical journey of hematology and oncology patients. In this review, we are trying to review the new elements and highlights that are shaping febrile neutropenia in nowadays.Recent findings: Introduction of risk-stratification, expanded use of granulocyte-colony stimulating factor and oral treatment for selected patients and rapid administration of antibiotics revolutionized the treatment of febrile neutropenia. Oral treatment with moxifloxacine or amoxicillin-clavulanate + ciprofloxacin has already been widely tested and is actually a standard of care for a meticulously selected group of patients managed as ambulatory patients. Intravenous treatment of febrile neutropenia is a major challenge for clinicians and microbiologists since the blast of the \"silent pandemic\" of antimicrobial resistance.Summary: In this setting, strategies that reduce the chances of febrile neutropenia, misuse of antibiotics and enhance the rigorous control of infections may offer a chance to improve the management of febrile neutropenia and offer to our patients the chance to continue their antineoplastic treatment without perturbations.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"163-167"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immuno-oncology in the daily practice.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-27 DOI: 10.1097/CCO.0000000000001117

Ariane Laparra

{"title":"Immuno-oncology in the daily practice.","authors":"Ariane Laparra","doi":"10.1097/CCO.0000000000001117","DOIUrl":"10.1097/CCO.0000000000001117","url":null,"abstract":"Purpose of review: Immune checkpoint inhibitors (ICI) have become an integral part of oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, ICI can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE). The spectrum of irAE and the time to onset can be very broad, sometimes leading to the patient's death.Additionally, ICI could be associated with chronic or long-term adverse events that impact quality of life. The expansion of the indications for immunotherapy in the early adjuvant and neoadjuvant stages is altering the benefit-risk balance of these therapies.Furthermore, the combination of immunotherapies with other oncology treatments makes the interpretation of adverse events difficult.To date, no predictive factors have been identified in routine practice to identify patients at risk of developing serious toxicity.Recent findings: This has led us to develop a patient care pathway dedicated to the management of these toxicities, enabling early detection of irAE to improve outcomes.Summary: We have presented a novel care pathway based on a clinical evaluation, encompassing a daily hospital devoted to the management of toxicities, an iTox multidisciplinary board, and a pharmacovigilance database. This pathway involves a translational research program.The toxicity day hospital allowed us to care for patients at an early stage of an adverse event and to establish whether anticancer treatment was responsible for the onset of symptoms and/or biological abnormalities.The objective of this pathway is to enhance the quality of life and compliance of oncology treatment, while minimizing the necessity for unscheduled care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"136-141"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001118

Oumnia Mouna, Charlotte Hanssens, Michel Meyers, Mireille Langouo

{"title":"Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.","authors":"Oumnia Mouna, Charlotte Hanssens, Michel Meyers, Mireille Langouo","doi":"10.1097/CCO.0000000000001118","DOIUrl":"10.1097/CCO.0000000000001118","url":null,"abstract":"Purpose of review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.Recent findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status. Instead, a shift towards observation combined with adjuvant therapies such as immune checkpoint inhibitors and targeted therapies (for BRAF-mutant melanoma) has been observed. These approaches have been associated with similar or improved recurrence-free survival rates and reduced treatment-related complications. However, challenges remain in establishing standardized protocols for adjuvant therapy use.Summary: The management of stage III melanoma is rapidly transitioning from routine CLND towards a more individualized approach that incorporates active surveillance and adjuvant therapies based on tumor biology and patient-specific factors. Multidisciplinary discussions are essential to guide treatment decisions, and further research is required to develop clear, evidence-based protocols.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"110-115"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to monitor the side effects of treatments in cancer patients.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-03 DOI: 10.1097/CCO.0000000000001123

Mario Di Palma

引用次数: 0

From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-23 DOI: 10.1097/CCO.0000000000001115

Carmen Orte Cano, Mariano Suppa, Ievgenia Pastushenko, Véronique Del Marmol

{"title":"From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma.","authors":"Carmen Orte Cano, Mariano Suppa, Ievgenia Pastushenko, Véronique Del Marmol","doi":"10.1097/CCO.0000000000001115","DOIUrl":"10.1097/CCO.0000000000001115","url":null,"abstract":"Purpose of review: Squamous cell carcinoma (SCC) is the second most common skin cancer, with an increasing incidence. This review highlights this past year's advances regarding the understanding of its pathogenesis, newly introduced diagnostic methods and updates in prevention and treatment.Recent findings: While the pathogenesis of SCC progression remains unclear, new sequencing techniques are helping to better characterize these tumours at the molecular level. Recently introduced noninvasive imaging techniques are rapidly transforming SCC diagnosis and follow-up. Although nicotinamide has not demonstrated significant benefit in reducing SCC incidence among transplant recipients, larger studies are needed to achieve statistical power. Tirbanibulin, a new field treatment for actinic keratosis is now available and well tolerated for use in areas up to 100 cm 2 . Surgery remains the cornerstone of SCC treatment and can now be complemented with cemiplimab, when advanced.Summary: Recent years have seen a diagnostic revolution in dermatology, driven by noninvasive imaging and artificial intelligence; however, the physiopathogenesis of SCC progression remains poorly understood. In treatment, immune checkpoint inhibitors have shown good survival outcomes for advanced SCC. Research continues in the neoadjuvant setting and among transplanted patients, with encouraging preliminary results.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"105-109"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of the microbiome in skin cancer development and treatment.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1097/CCO.0000000000001120

Anthony Martin Fuentes

{"title":"The role of the microbiome in skin cancer development and treatment.","authors":"Anthony Martin Fuentes","doi":"10.1097/CCO.0000000000001120","DOIUrl":"10.1097/CCO.0000000000001120","url":null,"abstract":"Purpose of review: Recent research underscores the significant influence of the skin and gut microbiota on melanoma and nonmelanoma skin cancer (NMSC) development and treatment outcomes. This review aims to synthesize current findings on how microbiota modulates immune responses, particularly enhancing the efficacy of immunotherapies such as immune checkpoint inhibitors (ICIs).Recent findings: The microbiota's impact on skin cancer is multifaceted, involving immune modulation, inflammation, and metabolic interactions. Beneficial strains like Bifidobacterium and Lactobacillus have shown potential in supporting anti-PD-1 and anti-CTLA-4 therapies by promoting T-cell activation and immune surveillance. Evidence from preclinical and clinical studies, including fecal microbiota transplantation (FMT), highlights improved response rates in patients with microbiota-rich profiles. Notably, certain bacterial metabolites, such as inosine, contribute to enhanced antitumor activity by stimulating IFN-γ in CD8 + T cells.Summary: Understanding the interplay between microbiota and skin cancer treatment opens promising avenues for adjunctive therapies. Probiotic and prebiotic interventions, FMT, and microbiota modulation are emerging as complementary strategies to improve immunotherapy outcomes and address treatment resistance in melanoma and NMSC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"121-125"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term immune related adverse events.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-16 DOI: 10.1097/CCO.0000000000001113

Leo Plaçais, Olivier Lambotte

引用次数: 0

Chemotherapy-induced nausea and vomiting: can we do better?

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1097/CCO.0000000000001114

Florian Scotté

{"title":"Chemotherapy-induced nausea and vomiting: can we do better?","authors":"Florian Scotté","doi":"10.1097/CCO.0000000000001114","DOIUrl":"10.1097/CCO.0000000000001114","url":null,"abstract":"Purpose of review: Although the management of nausea and vomiting induced by cancer treatments has evolved, several questions remain unanswered.Recent findings: New antiemetics have been developed these last decades with therapeutic indications to be defined according to the anticancer regimen and partly as a consequence of the assessment of individual patient risk factors. Guidelines still seem to have a low level of knowledge and compliance, with a role for scientific societies in term of dissemination and education. A number of persistent issues relating to emesis still need improvement in prevention and management. Nausea remains a subjective semantic whose evaluation should possibly benefit from educational programs. The risk classification of anticancer drugs must be regularly updated, requiring regular literature reviews and the integration of data from clinical trials relating to emerging anticancer drugs. Recent data, particularly in the context of emerging drugs, highlight the importance to consider emesis' impact beyond the 5-day period, with a potential adaptation of antiemetic prophylaxis, including the mode of administration of oral drugs.Summary: Guidelines update is presented with literature answers to the current issues in order to improve quality of patient's management in the context of emesis related to anticancer therapies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"158-162"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1097/CCO.0000000000001121

引用次数: 0